David S. Wichmann - 21 May 2025 Form 4 Insider Report for Privia Health Group, Inc. (PRVA)

Reporting relationship: Director
Issuer ticker: PRVA
Reported as of: 21 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 May 2025, 17:03:50 UTC
Prior SEC filing: 09 May 2025
Next SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Anita Beth Adams, as attorney-in-fact

Key filing fact

David S. Wichmann filed Form 4 for Privia Health Group, Inc. (PRVA) on 23 May 2025.

Key facts

This page summarizes David S. Wichmann's Form 4 filing for Privia Health Group, Inc. (PRVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 May 2025, 17:03.

Change

Previous filing in this sequence was filed on 09 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001268489 Primary reporting owner

WICHMANN DAVID S

Relationship: Director
Address: PRIVIA HEALTH GROUP, INC., 950 N. GLEBE ROAD, SUITE 700, ARLINGTON
Signature: /s/ Anita Beth Adams, as attorney-in-fact
Signature date: 23 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRVA transaction

Common Stock, par value $0.01 per share

Award

Transaction value: $0
Shares: +8,396
Change %: +48%
Price: $0.000000
Shares after: 25,709
Date: 21 May 2025
Ownership: Direct
Footnotes: F1

PRVA holding

Common Stock, par value $0.01 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,315,340
Date: 21 May 2025
Ownership: See Footnote
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On May 21, 2025, the reporting person received 8,396 restricted stock units under the Issuer's 2021 Omnibus Incentive Plan. The restricted stock units will vest on the earlier of (i) the day immediately preceding the Company's 2026 annual meeting of stockholders and (ii) the first anniversary of the date of the grant.

Footnote F2

Represents shares held by Jory Capital, LLC, which is co-owned by the Reporting Person.